Results 131 to 140 of about 991,242 (315)

Finite element modelling of concrete-filled square stainless steel tubular stub columns under axial compression

open access: yes, 2009
Concrete-filled stainless steel tubes can be considered as a new and innovative kind of composite construction technique, and have the potential to be used extensively in civil engineering.
Uy, Brian (R9735)   +3 more
core  

TECHNOLOGY OF PRODUCTION OF HIGH-STRENGTH REINFORCING STEEL

open access: yesЛитьë и металлургия, 2004
The technology of the high-strength spiral hardware is considered in the article. The offered technology allows to bring the mechanical characteristics of high-strength reinforcing steel to conformity with the requirements of practically all the well ...
A. N. Bondarenko   +3 more
doaj  

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec   +6 more
wiley   +1 more source

United States Steel Keewatin Taconite Mine & Plant

open access: yes, 2015
aerial view, U.S. Steel Keewatin Taconite Mine & Plant, located in the Mesabi Iron Range in northern Minnesota, 8/25/2010Sparrows Point, MD ...
United States Steel Corporation
core  

Rolling out defects during rolling of castings at the mill 850 of Belarussian metallurgical plant

open access: yesЛитьë и металлургия, 2001
Results of industrial experiment are given and regularities of rolling out of surface defects of artificial origin are investigated at rolling of continuous castings at the rolling mill 850 of Belarussian metallurgical ...
V. I. Scherbakov   +3 more
doaj  

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

United States Steel Clairton Plant

open access: yes, 1916
aerial view, industrial infrastructure at the US Steel Corporation Clairton Plant; this is the largest coke manufacturing facility in the US, producing 4.7 million tons of coke annually; derived from coal, coke is the commonly used fuel for smelting iron,
United States Steel Corporation
core  

White Matter Hyperintensity Burden and Short‐Interval Change Associated With Sleep Apnoea in the UK Biobank

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng   +4 more
wiley   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy